4.4 Article

Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis

Journal

SCHIZOPHRENIA RESEARCH
Volume 193, Issue -, Pages 188-196

Publisher

ELSEVIER
DOI: 10.1016/j.schres.2017.06.032

Keywords

Psycosis; Metabolism; Metabolic syndrome; Diabetes; Schizophrenia; Antipsychotics

Categories

Funding

  1. Ministerio de Economia y Competitividad [ISCIII 2009-2011, PI 080208]
  2. Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Union Europea, Un manera de hacer Europa
  3. Centro de Investigacion Biomedica en Red de salud Mental, CIBERSAM
  4. CERCA Programme/Generalitat de Catalunya
  5. Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement [2014SGR441]

Ask authors/readers for more resources

Patients with a first episode of psychosis (FEP) display a broad range of metabolic risk factors related to the development of diverse medical comorbidities. Initial stages of these disorders are essential in understanding the increased vulnerability of developing cardiometabolic disturbances, associated with a reduced life expectancy. This study aimed to evaluate the metabolic profile of a cohort of patients with a FEP and its evolution during a two year follow-up, as well as the factors that influence the changes in their metabolic status. 16 participating centers from the PEPs Project recruited 335 subjects with a FEP and 253 matched healthy controls, aged 9-35 years. We investigated a set of anthropometric measures, vital signs and laboratory data obtained from each participant over two years in a prospective, naturalistic study. From the beginning of the study the FEP group showed differences in the metabolic profile compared to the control group, together with a progressive worsening in the major part of the analyzed variables during the followup period, with higher rates of obesity and metabolic syndrome. Certain risk factors were related to determinate clinical variables such as male gender, the presence of affective symptoms or an early onset or to treatment variables such as the use of antipsychotic polypharmacy, antidepressants or mood stabilizers. Our results highlight the extremely high risk of patients at early phases of schizophrenia and other psychotic disorders of developing cardiovascular comorbidity and the fast worsening of the metabolic profile during the first two years. (c) 2017 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available